Analyst consensus rating
Editas Medicine Analyst Rating: Buy
Direct answer
Editas Medicine's consensus rating is Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.10.
Forecast evidence checked October 17, 2026.
Get free Editas Medicine email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.35
- Average price target
- $6.10
- High price target
- $15.00
- Low price target
- $1.00
- Low target gap
- -57.4%
- Target upside
- +159.6%
- High target gap
- +538.3%
- Target range width
- 595.7%
- Consensus rating
- Buy
- Analysts
- 10
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Editas Medicine?
Editas Medicine has a verified Buy consensus. The same dataset has an average price target of $6.10.
How far are Editas Medicine's low and high targets from the recorded price?
The low target implies -57.4%, while the high target implies +538.3%.
How many analysts are included in Editas Medicine's consensus?
The verified consensus includes 10 analysts.
How is Editas Medicine's target upside or downside calculated?
The average target of $6.10 is divided by the recorded price of $2.35, then one is subtracted to produce +159.6%. This does not guarantee a future return.
When was Editas Medicine's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.